Mesa Laboratories Inc /co/ (MLAB) · Aug 10, 2026 · Earnings

Margins beat expectations despite weak SDC execution and nearly flat sales

Margins beat expectations despite weak SDC execution and nearly flat sales

The quarter was roughly in line on adjusted earnings, not a clean beat. Adjusted operating income per diluted share was $2.61 versus a published consensus of approximately $2.63, a narrow shortfall; excluding the $382,000 legal settlement, it was $2.68, modestly above expectations. Revenue rose only 1.0% to $60.1 million, while core organic growth was just 0.4% (Financial Highlights).

Metric1Q271Q26Versus expectation
Revenue$60.138M$59.543MNo reliable published consensus found
Core organic revenue growth0.4%—Low underlying growth (Financial Highlights)
AOI$15.035M$12.902M— (Non-GAAP reconciliation)
AOI excluding unusual items$15.417M$12.902MAbove on adjusted earnings (Non-GAAP reconciliation)
Adjusted diluted operating-income per share$2.61$2.32About $0.02 below published consensus
Adjusted diluted operating-income per share, excluding unusual items$2.68$2.32Above published consensus

Profitability was the clear upside surprise. AOI excluding unusual items increased 19.5% and reached 25.6% of revenue, up from 21.7% a year earlier, despite additional investment in SDC (Non-GAAP reconciliation; Management commentary). Gross-margin improvement in BPD, Calibration Solutions, and Clinical Genomics offset weaker performance in the largest division.

The revenue mix still exposes an execution problem. SDC, representing 41% of revenue, declined 3.6% organically because fulfillment and delivery issues delayed customer shipments, and its gross-profit percentage fell 150 basis points (Segment results — Sterilization and Disinfection Control). Growth in BPD and Calibration Solutions—5.0% and 7.6%, respectively—was enough to stabilize total sales but not to produce broad-based acceleration (Segment results — BPD; Segment results — Calibration Solutions).

The balance sheet improved, but the outlook remains deliberately incomplete. Mesa repaid $8.656 million of debt and reduced its total net leverage ratio to 1.85, below its stated 2.0 target (Management commentary). However, management deferred full-year guidance until November, so the filing improves confidence in margins and deleveraging without materially changing the revenue outlook. Reported net income fell 40.3% to $2.830 million, but that comparison was distorted by a roughly $6.15 million foreign-currency gain in the prior-year quarter (Income Statement; Management commentary).

Original filing on SEC EDGAR

More Mesa Laboratories Inc /co/ news

Margins beat expectations despite weak SDC execution and nearly flat sales | MLAB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.